Fondazione Callerio

Aggiornamento di risultati pubblicati

(nell'originale inglese)

M. Lucafò, S. Pacor, C. Fabbro, T. Da Ros, S. Zorzet, M. Prato, G. Sava.
Study of a potential drug delivery system based on carbon nanoparticles: effects of fullerene derivatives in MCF7 mammary carcinoma cells.
J Nanopart Res 2012, 14:1-13. Abstract

Vidimar V, Meng X, Klajner M, Licona C, Fetzer L, Harlepp S, Hébraud P, Sidhoum M, Sirlin C, Loeffler JP, Mellitzer G, Sava G, Pfeffer M, Gaiddon C.
Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity.
Biochem Pharmacol 2012, 84:1428-1436. Abstract

Vadori M, Pacor S, Vita F, Zorzet S, Cocchietto M, Sava G.
Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice.
J Inorg Biochem 2012, 118C:21-27. Abstract

Sava G, Jaouen G, Hillard EA, Bergamo A.
Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.
Dalton Trans, 2012, 41: 8226-34. Abstract

Bratsos I, Mitri E, Ravalico F, Zangrando E, Gianferrara T, Bergamo A, Alessio E.
New half sandwich Ru(II) coordination compounds for anticancer activity.
Dalton Trans, 2012, 41: 7358-71. Abstract

Bergamo A, Gaiddon C, Schellens JHM, Beijnen JH, Sava G.
Approaching tumour therapy beyond platinum drugs, status of the art and perspectives of ruthenium drug candidates.
J Inorg Biochem, 2012, 106: 90-9. ISBN/ISSN: 0162-0134. Abstract

Ang WH, Casini A, Sava G, Dyson PJ.
Organometallic ruthenium-based antitumor compounds with novel modes of action.
Organomet Chem 2011, 696:989-998. Abstract

Mendes F, Groessl M, Nazarov AA, Tsybin YO, Sava G, Santos I, PJ Dyson, Casini A.
Metal-based inhibition of poly(ADP-ribose) polymerase – the guardian angel of DNA.
J Med Chem 2011, 54:2196-2206. Abstract

Sava G, Bergamo A, Dyson PJ.
Metal-based antitumour drugs in the post-genomic era: what comes next?
Dalton Trans, 40: 9069-75, 2011. Abstract

Bratsos, C. Simonin, E. Zangrando, T. Gianferrara, A. Bergamo, E. Alessio.
New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behaviour and in vitro anticancer activity.
Dalton Trans, 2011, 40: 9533-43. DOI: 10.1039/c1dt11043h. Abstract

Alberta Bergamo and Gianni Sava.
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
Dalton Trans, 40: 7817-23, 2011. doi: 10.1039/c0dt01816c. ISBN/ISSN: 1477-9226. Abstract

Quiroga AG, Ramos-Lima FJ, Alvarez-Valdes A, Font-Bardia M, Bergamo A, Sava G, Navarro-Ranninger C.
Synthesis, characterization and tumor cell growth inhibition of new trans platinum complexes with phosphane derivatives.
Polyhedron, 30: 1646-50, 2011. doi: 10.1016/j.poly.2011.03.034. ISBN/ISSN: 0277-5387. Abstract

Bergamo A, Masi A, Peacock AFA, Habtemariam A, Sadler PJ, Sava G.
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model.
J Inorg Biochem, 104(1):79-86. DOI: 10.1016/j.jinorgbio.2009.10.005. Abstract

Bergamo A, Masi A, Jakupec MA, Keppler BK, Sava G.
Inhibitory effects of the ruthenium complex KP1019 in models of mammary cancer cell migration and invasion.
Met Based Drugs, 2009: 681270, Epub 2009 Sep 17. Abstract

Sava G, Bergamo A.
Ruthenium drugs for cancer chemotherapy: an ongoing challenge to treat solid tumours.
In: Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy, A. Bonetti et al. (eds), Humana Press. a part of Springer Science + Business Media. LLC 2009, pag: 57-66. Abstract

Bergamo A, Masi A, Dyson PJ, Sava G.
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.
Int J Oncol, 33: 1281-1289, 2008. ISBN/ISSN: 1019-6439. Abstract

Bratsos I, Bergamo A, Sava G, Gianferrara T, Zangrando E, Alessio E.
Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors.
J Inorg Biochem, 102:606-617, 2008. ISBN/ISSN: 0162-0134. Abstract

Cocchietto M, Zorzin L, Veronesi PA, Sava G.
Oral poly(ethylene glycol)-coniugated human recombinant lysozyme control of lung metastases in mice.
Mol Med Rep. 1:847-850, 2008. Abstract

Cocchietto M, Zorzin L, Toffoli B, Candido R, Fabris B, Stebel M, Sava G.
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy.
Diabetes & Metabolism 34:587-594, 2008. Abstract

Pellizzaro C, Speranza A, Zorzet S, Crucil I, Sava G, Scarlata I, Cantoni S, Fedeli M, Coradini D. I
Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report.
Pancreas 36:e15-23, 2008. Abstract

Bratsos I, Jedner S, Bergamo A, Sava G, Gianferrara T, Zangrando E, Alessio E.
Half-sandwich Ru(II)[9]aneS(3) complexes structurally similar to antitumor-active organometallic piano-stool compounds: Preparation, structural characterization and in vitro cytotoxic activity.
J Inorg Biochem. 102:1120-1133, 2008. Abstract

Griffith D, Cecco S, Zangrando E, Bergamo A, Sava G, Marmion CJ.
Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation.
J Biol Inorg Chem. 13:511-520, 2008. Abstract

Sava G.
Metal based drugs restyled and resumed.
Met. Based Drugs 2007:16260, 2007. Abstract

Bratsos I, Bergamo A, Sava G, Gianferrara T, Zangrando E, Alessio E.
Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors.
J Inorg Biochem. 2007 Oct 24 [Epub ahead of print]. Abstract

Scolaro C, Chaplin AB, Hartinger CG, Bergamo A, Cocchietto M, Keppler BK, Sava G, Dyson PJ.
Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
Dalton Transactions. 2007 Nov 14;(43):5065-72. Epub 2007 Sep 26. Abstract

Griffith D, Bergamo A, Pin S, Vadori M, Muller-Bunz H, Sava G, Marmion CJ.
Novel platinum pyridinehydroxamic acid complexes: synthesis, characterisation, X-ray crystallographic study and nitric oxide relaled properties.
Polyhedron 26:4697-4706, 2007. Abstract

Vock CA, Ang WH, Scolaro C, Phillips AD, Lagopoulos L, Juillerat-Jeanneret L, Sava G, Scopelliti R, Dyson PJ.
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms.
J Med Chem. 50:2166-2175, 2007. Abstract

Bergamo A, Sava G.
Ruthenium complexes can target determinants of tumour malignancy.
Dalton Transactions, 7:1267-1272, 2007. Abstract

Grabnar I, Maggi L, Cocchietto M, Conte U, Voinovich D.
Bioavailability of metoclopramide from a new chewing gum device.
J Drug Del Sci Tech, 17:173-176, 2007. Abstract

Zorzin L, Cocchietto M, Voinovich D, Marcuzzi A, Filipovic-Grcic J, Mulloni C, Grembiale G, Casarsa C, Bulla R, Sava G.
Lysozyme-containing chitosan-coated arginate microspheres for oral immunisation.
J. Drug Del. Sci. Tech., 16:413-420, 2006. Abstract

Vock CA, Scolaro C, Phillips AD, Scopelliti R, Sava G, Dyson PJ.
Synthesis, Characterization, and in Vitro Evaluation of Novel Ruthenium(II) eta(6)-Arene Imidazole Complexes.
J. Med. Chem., 49:5552-5561, 2006. Abstract

Khalaila I, Bergamo A, Bussy F, Sava G, Dyson PJ.
The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.
Int J Oncol. 29:261-268, 2006. Abstract

Dyson PJ, Sava G.
Metal-based antitumour drugs in the post genomic era.
Dalton Trans., 16:1929-1933, 2006. Abstract

Coradini D, Pellizzaro C, Scarlata I, Zorzet S, Garrovo C, Abolafio G, Speranza A, Fedeli M, Cantoni S, Sava G, Daidone MG, Perbellini A.
A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results.
Organometallics, 25:756-765, 2006. Abstract

Scolaro C, Geldbach TJ, Rochat S, Dorcier A, Gossens C, Bergamo A, Cocchietto M, Tavernelli I, Sava G, Rothlisberger U, Dyson PJ.
Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds.
Organometallics, 25:756-765, 2006. Abstract

Gava B, Zorzet S, Spessotto P, Cocchietto M, Sava G.
Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion.
J Pharmacol Exp Ther, 317:284-291, 2006. Abstract

Paolini A, Ridolfi V, Zezza D, Cocchietto M, Musa M, Pavone A, Conte A, Giorgetti G.
Vaccination trial of sea-bass (Dicentrarchus labrax) against pasteurellosis using oral, intraperitoneal and bath administration.
Veterinaria Italiana, 41:7-14, 2005. Abstract

Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, Geldbach TJ, Sava G, Dyson PJ.
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
J Med Chem, 48:4161-4171, 2005. Abstract

Papadia P, Margiotta N, Bergamo A, Sava G, Natile G.
Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition.
J Med Chem, 48:3364-3371, 2005. Abstract

Frausin F, Scarcia V, Cocchietto M, Furlani A, Serli B, Alessio E, Sava G.
Free Exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cells.
J Pharmacol Exp Ther, 313: 227-233, 2005. Abstract

Alessio E, Mestroni G, Bergamo A, Sava G.
Ruthenium antimetastatic agents.
Curr Top Med Chem, 4:1525-1535, 2004. Abstract

Casarsa C, Mischis MT, Sava G.
TGFß1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours.
J Inorg Biochem, 98:1648-1654, 2004. Abstract

Margiotta N, Bergamo A, Sava G, Padovano G, De Clercq E, Natile G.
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir.
J Inorg Biochem, 98: 1385-1390, 2004. Abstract

Coradini D, Zorzet S, Rossin R, Scarlata I, Pellizzaro C, Turrin C, Bello M, Cantoni S, Speranza A, Sava G, Mazzi U, Perbellini A.
Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.
Clin. Cancer Res, 10: 4822-4830, 2004. Abstract

Bacac M, Vadori M, Sava G, Pacor S.
Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells.
Cancer Immunol Immunother, 53: 1101-1110, 2004. Abstract

Alessio E, Mestroni G, Bergamo A, Sava G.
Ruthenium anticancer drugs.
Met Ions Biol Syst, 42: 323-351, 2004. Abstract

Sava G, Frausin F, Cocchietto M, Vita F, Podda E, Spessotto P, Furlani A, Scarcia V, Zabucchi G.
Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.
Eur J Cancer, 40: 1383-1396, 2004. Abstract

Ravera M, Baracco S, Cassino C, Colangelo D, Bagni G, Sava G, Osella D.
Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases.
J Inorg Biochem, 98: 984-90, 2004. Abstract

Coradini D, Pellizzaro C, Abolafio G, Bosco M, Scarlata I, Cantoni S, Stucchi L, Zorzet S, Turrin C, Sava G, Perbellini A, Daidone MG.
Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study.
Invest New Drugs, 22: 207-217, 2004. Abstract

Pacor S, Zorzet S, Cocchietto M, Bacac M, Vadori M, Turrin C, Gava B, Castellarin A, Sava G.
Intra-tumoral nami-a treatment triggers metastasis reduction, which correlates to cd44 regulation and til recruitment.
J Pharmacol Exp Ther, 310(2):737-44, 2004. Abstract

Hotze AC, Caspers SE, De Vos D, Kooijman H, Spek AL, Flamigni A, Bacac M, Sava G, Haasnoot JG, Reedijk J.
Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)(2)Cl(2)] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)(2)Cl(2)].
J Biol Inorg Chem, 9(3):354-64, 2004. Abstract

Bouma M, Nuijen B, Challa EE, Sava G. Flaibani A, Bult A, Beijnen JH.
Stability and compatibility of the investigational antimetastatic ruthenium complex NAMI-A in infusion systems and its haemolytic potential.
J Oncol Pharm Practice, 10: 7-15, 2004. Abstract

Velders AH, Bergamo A, Alessio E, Zangrando E, Haasnoot JG, Casarsa C, Cocchietto M, Zorzet S, Sava G.
Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)] and [mer-RuCl3(H20)(dmso-S)(dmtp= 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
J Med Chem, 47: 1110-1121, 2004. Abstract

Bacac M, Hotze AC, Schilden K, Haasnoot JG, Pacor S, Alessio E, Sava G, Reedijk J.
The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
J Inorg Biochem, 98: 402-12, 2004. Abstract

Turel I, Pecanac M, Golobic A, Alessio E, Serli B, Bergamo A, Sava G.
Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives.
J Inorg Biochem., 98: 393-401, 2004. Abstract

Ferrari MB, Bisceglie F, Pelosi G, Tarasconi P, Albertini R, Dall'Aglio PP, Pinelli S, Bergamo A, Sava G.
Synthesis, characterization and biological activity of copper complexes with pyridoxal thiosemicarbazone derivatives. X-ray crystal structure of three dimeric complexes.
J Inorg Biochem, 98: 301-312, 2004. Abstract

Bergamo A, Stocco G, Casarsa C, Cocchietto M, Alessio E, Serli B, Zorzet S, Sava G.
Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
Int J Oncol, 24: 373-9, 2004. Abstract

Morbidelli L, Donnini S, Filippi S, Messori L, Piccioli F, Orioli P, Sava G, Ziche M.
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.
Brit J Cancer, 88: 1481-1491, 2003. Abstract

Messori L, Marcon G, Orioli P, Fontani M, Zanello P, Bergamo A, Sava G, Mura P.
Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)],(I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes.
J Inorg Biochem, 95: 37: 37-46, 2003. Abstract

Bergamo A, Messori L, Piccioli F, Cocchietto M and Sava G.
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.
Investigational New Drugs. 21: 401-11, 2003. Abstract

Sava G, Zorzet S, Turrin C, Vita F, Soranzo MR, Zabucchi G, Cocchietto M, Bergamo A, Digiovine S, Pezzoni G, Sartor L and Garbisa S.
Dual Action of NAMI-A in Inhibition of Solid Tumor Metastasis: Selective Targeting of Metastatic Cells and Binding to Collagen.
Clinical Cancer Research 9: 1898-905, 2003. Abstract

Bergamo A, Stocco G, Gava B, Cocchietto M, Alessio E, Serli B, Iengo E and Sava G.
Distinct Effects of Dinuclear Ruthenium(III) Complexes on Cell Proliferation and on Cell Cycle Regulation in Human and Murine Tumor Cell Lines.
The Journal of Pharmacology and Experimental Therapeutics. 305: 725-32, 2003. Abstract

Cocchietto M, Zorzet S, Sorc A and Sava G.
Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration.
Investigational New Drugs 21: 55-62, 2003. Abstract

Bouma M, Nuijen B, Jansen MT, Sava G, Picotti F, Flaibani A, Bult A, Beijnen JH.
Development of a LC method for pharmaceutical quality control for the antimetastatic ruthenium complex NAMI-A.
J Pharm Biomed Anal, 31: 215-228, 2003. Abstract

Akbayeva DN, Gonsalvi L, Oberhauser W, Peruzzini M, Vizza F, Brugeller P, Romerosa A, Sava G, Bergamo A.
Synthesis catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA Complexes [(C5R5)RuCl(PTA)2] (R= H, Me; PTA= 1,2,3-triaza-7-phosphaadamantane).
Chem Commun, 264-265, 2003. Abstract

Pintus G, Tadolini B, Posadino AM, Sanna B, Debidda M, Bennardini F, Sava G, Ventura C.
Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation.
Eur J Biochem, 269: 5861-5870, 2002. Abstract

Frausin F, Cocchietto M, Bergamo A, Scarcia V, Furlani A and Sava S.
Tumour cell uptake of metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells.
Cancer Chemother Pharmacol 50: 405-411, 2002. Abstract

Bergamo A, Gava B, Alessio E, Mestroni G, Serli B, Cocchietto M, Zorzet S and Sava G.
Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
International Journal of Oncology 21: 1331-1338, 2002. Abstract

Aggiornamento di risultati pubblicati (pagina 2)


Articoli per tutti